Louisiana Medicaid
Ophthalmic Disorders – Glaucoma Agents, Intraocular Pressure (IOP) Reducers

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request prior authorization for non-preferred intraocular pressure reducers.

Additional Point-of-Sale edits may apply.

By submitting the authorization request, the prescriber attests to the conditions available HERE.
~~*These agents may have **Black Box Warnings** and/or may be subject to **Risk Evaluation and Mitigation Strategy (REMS)** under FDA safety regulations. Please refer to individual prescribing information for details.*~~

Approval Criteria for Initiation and Continuation of Therapy~~Approval Criteria for Initial and Reauthorization Requests~~

- ~~For brimonidine 0.15% (generic for Alphagan P® 0.15%) – there has been a treatment failure or intolerable side effect with or contraindication to brand Alphagan P® 0.15%; **OR**~~
- ~~For brimonidine/timolol (generic and authorized generic for Combigan®) – there has been a treatment failure or intolerable side effect with or contraindication to brand Combigan®; **OR**~~
- There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc.; **AND**
- Previous use of a preferred product - **ONE** of the following is required:
  - The recipient has had a *treatment failure* with at least one preferred product; **OR**
  - The recipient has had an *intolerable side effect* to at least one preferred product; **OR**
  - The recipient has *documented contraindication(s)* to all of the preferred products that are appropriate to use for the condition being treated; **OR**
  - There is *no preferred product that is appropriate* to use for the condition being treated; **OR**
  - The prescriber states that the recipient is currently using the requested medication.~~;~~ ~~**AND**~~
- ~~By submitting the authorization request, the prescriber attests to the following:~~
  - ~~The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**~~
  - ~~All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**~~
  - ~~The recipient has no concomitant drug therapies or disease states that limit the use of the requested medication and will not be receiving the requested medication in combination with any other medication that is contraindicated or not recommended per FDA labeling.~~

Duration of approval for initiation and continuation of therapy~~Duration of initial and reauthorization approval~~: 12 months

References

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; https://www.clinicalkey.com/pharmacology/

DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach, 10e New York, NY: McGraw-Hill; https://accesspharmacy.mhmedical.com/book.aspx?bookid=1861

Revision / Date	Implementation Date
Single PDL Implementation	May 2019
Added specific wording for use of Alphagan P® 0.15%, separated "Select Therapeutic Classes (Established)" into individual therapeutic class documents / November 2019	January 2020
Added preferred brand wording for use of Travatan Z®; formatting changes, added reference / November 2020	January 2021
Formatting changes; updated references / September 2021	January 2022
Added wording for use of Combigan® / November 2022	January 2023
Removed wording for use of -Travatan Z® / October 2023	January 2024
Removed specific wording for the use of Alphagan P® 0.15% and Combigan®, formatting changes / April 2024	July 2024